C3 and lupus nephritis: However, until early 2023, the approved complement therapeutics now includes the anti-C5 mAbs eculizumab (Soliris, Alexion) and ravulizumab (Ultomiris, Alexion), the C3-inhibitory peptide pegcetacoplan (Empaveli/Aspaveli, Apellis), the C5a receptor 1 antagonist avacopan (Tavneos, Chemocentryx/Vifor), the anti-C1s mAb sutimlimab (Enjaymo, Sanofi), etc., and patients, including lupus nephritis patients, may benefit from those biological agents [46].